Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Institutions
Jikei University School of Medicine (JP)
University of Parma (IT)
Royal Marsden NHS Foundation Trust (GB)
Innsbruck Medical University (AT)
Ankara University (TR)
Universität Innsbruck (AT)
Charles University (CZ)
University Hospital Bonn (DE)
Ochsner Medical Center (US)
Hospital Israelita Albert Einstein (BR)
Policlinico Umberto I (IT)
Markey Cancer Center (US)
Popular University of Cesar (CO)
Tawam Hospital (AE)
The University of Kansas Cancer Center (US)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
Azienda USL di Bologna (IT)
Institutul Oncologic Bucuresti (RO)
Instituto Alexander Fleming (AR)
Hospital Materno-Infantil (ES)
University Hospital Hradec Králové (CZ)
Hospital Sírio-Libanês (BR)
The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Journal
Cancer Immunology Immunotherapy
Topics
Bladder and Urothelial Cancer Treatments
article
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
article en
Abstract
No abstract available for this paper.
Publication Tag
Cancer Immunology ImmunotherapyVol. 75(4)
Institutions
Jikei University School of Medicine (JP), University of Parma (IT), Royal Marsden NHS Foundation Trust (GB), Innsbruck Medical University (AT), Ankara University (TR), Universität Innsbruck (AT), Charles University (CZ), University Hospital Bonn (DE), Ochsner Medical Center (US), Hospital Israelita Albert Einstein (BR), Policlinico Umberto I (IT), Markey Cancer Center (US), Popular University of Cesar (CO), Tawam Hospital (AE), The University of Kansas Cancer Center (US), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), Azienda USL di Bologna (IT), Institutul Oncologic Bucuresti (RO), Instituto Alexander Fleming (AR), Hospital Materno-Infantil (ES), University Hospital Hradec Králové (CZ), Hospital Sírio-Libanês (BR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), MD Anderson Cancer Center Madrid (ES), Hospital Universitario Ramón y Cajal (ES), Ospedale di Macerata, University of Macerata (IT), Kindai University (JP), University of Bologna (IT)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV) · Cancer Immunology Immunotherapy (2026) | TGRS Research Map | TGRS